Evidence map›Paper›PMID 35118159›Full record

ArticleBioMed research international2022

Solidified Reverse Micellar Solution- (SRMS-) Based Microparticles for Enhanced Oral Bioavailability and Systemic Antifungal Efficacy of Miconazole Nitrate in Immunocompromised Mice.

Emmanuel Maduabuchi Uronnachi, Anthony Attama, Franklin Kenechukwu, Chukwuebuka Umeyor, Thaddeus Gugu, Calistus Nwakile, Chidalu Ikeotuonye

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BioMed research international, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.4field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Emmanuel Maduabuchi UronnachiNanomedicines and Drug Delivery Research Group, Department of Pharmaceutics and Pharmaceutical Technology, Nnamdi Azikiwe University, Awka, 422001 Anambra State, Nigeria.ORCID https://orcid.org/0000-0001-8885-9271
Anthony AttamaDrug Delivery and Nanomedicines Research Group, Department of Pharmaceutics, University of Nigeria, Nsukka, 410001 Enugu State, Nigeria.ORCID https://orcid.org/0000-0002-5751-2280
Franklin KenechukwuDrug Delivery and Nanomedicines Research Group, Department of Pharmaceutics, University of Nigeria, Nsukka, 410001 Enugu State, Nigeria.ORCID https://orcid.org/0000-0002-1619-4474
Chukwuebuka UmeyorNanomedicines and Drug Delivery Research Group, Department of Pharmaceutics and Pharmaceutical Technology, Nnamdi Azikiwe University, Awka, 422001 Anambra State, Nigeria.ORCID https://orcid.org/0000-0001-8674-0867
Thaddeus GuguDepartment of Pharmaceutical Microbiology and Biotechnology, University of Nigeria, Nsukka, 410001 Enugu State, Nigeria.ORCID https://orcid.org/0000-0003-4840-4090
Calistus NwakileNanomedicines and Drug Delivery Research Group, Department of Pharmaceutics and Pharmaceutical Technology, Nnamdi Azikiwe University, Awka, 422001 Anambra State, Nigeria.ORCID https://orcid.org/0000-0002-4080-5773
Chidalu IkeotuonyeNanomedicines and Drug Delivery Research Group, Department of Pharmaceutics and Pharmaceutical Technology, Nnamdi Azikiwe University, Awka, 422001 Anambra State, Nigeria.
Nnamdi Azikiwe University · NGUniversity of Nigeria · NG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo assess the improvement in oral bioavailability and efficacy in systemic candidiasis treatment of miconazole nitrate (MN) formulations in murine models of candidiasis.

methodsSelected formulations containing 5% of Softisan + Phospholipon 90H lipid matrix with 3% of MN (

resultsThe lipid formulations were safer than MN powder with LD

conclusionFormulation

Indexed as

Antifungal AgentsMiconazoleAnimalsBiological AvailabilityCandida albicansCandidiasisLipidsMiceMicellesParticle SizePowdersAntifungal AgentsLipidsMicellesMiconazolePowders

Identifiers

PMID35118159
PMCPMC8807030
OpenAlexW4210771899

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.